Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Zai Lab Ltd ( (HK:9688) ) is now available.
Zai Lab Limited reported a 22% year-over-year increase in total revenues for the first quarter of 2025, reaching $106.5 million, and is on track to achieve profitability by the fourth quarter of 2025. The company is advancing its oncology pipeline with promising data presentations and is poised for growth with a strong cash position and expanding global portfolio, aiming to drive long-term shareholder value.
More about Zai Lab Ltd
Zai Lab Limited is a biopharmaceutical company focused on developing and commercializing innovative therapies, primarily in the field of oncology. The company is expanding its global portfolio and aims to become a leading player in the biopharmaceutical industry.
Average Trading Volume: 8,916,837
Technical Sentiment Signal: Buy
Current Market Cap: HK$26.04B
For a thorough assessment of 9688 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue